Case report and review: alloimmunization, delayed hemolytic transfusion reaction, and clinically significant anti-Yta in a patient with ²-thalassemia/sickle cell anemia

1. Davis JR, Vinchinsky E, Lubin BH. Current treatment of sickle cell disease. Curr Prob Pediatr 1980;10:1–8.10.1016/S0045-9380(80)80007-7Search in Google Scholar

2. Koshy M, Burd L, Wallace D, et al. Prophylactic red cell transfusions in pregnant patients with sickle cell disease. N Engl J Med 1988;319:1447–52.10.1056/NEJM1988120131922043054555Search in Google Scholar

3. Walker RH, ed. Technical manual. 10th ed. Arlington, VA: American Association of Blood Banks; 1990:539–40.Search in Google Scholar

4. Rodgers GP. Recent approaches to the treatment of sickle cell anemia. JAMA 1991;265:2097–101.10.1001/jama.1991.03460160075033Search in Google Scholar

5. Milner PF, Squires JE, Larison PJ, Charles WT, Krauss JS. Posttransfusion crises in sickle cell anemia: role of delayed hemolytic reactions to transfusion. Southern Med J 1985; 78: 1462–9.10.1097/00007611-198512000-000164071176Search in Google Scholar

6. Charache S. Problems in transfusion therapy (editorial). N Engl J Med 1990;322:1666–8.10.1056/NEJM1990060732223092342526Search in Google Scholar

7. Ballas SK, Sherwood WC. Rapid in vivo destruction of Yt(a+) erythrocytes in a recipient with anti-Yt^a. Transfusion 1977;17:65-610.1046/j.1537-2995.1977.17177128889.x841677Search in Google Scholar

8. Levy GJ, SelSet G, McQuisten D, et al. Clinical significance of anti-Ytb: report of a case using a ⁵¹chromium red cell survival study. Transfusion 1988;28:265–7.10.1046/j.1537-2995.1988.28388219157.x3285526Search in Google Scholar

9. Giles CM, Metaxas MN. Identification of the predicted blood group antibody anti-Ytb. Nature 1964;202:1122–4.10.1038/2021122a014207215Search in Google Scholar

10. Levene C, Bar-Shany S, Manny N, Moulds JJ, Cohen T. The Yt blood groups in Israeli Jews, Arabs, and Druse. Transfusion 1987;27:47–14.10.1046/j.1537-2995.1987.27688071697.x3686656Search in Google Scholar

11. AuBuchon JP, Brightman A, Anderson JH, Kim B. An example of anti-Yta demonstrating a change in its clinical significance. Vox Sang 1988;55:171–5.Search in Google Scholar

12. Person HA. Vertrees KM. Site of binding of chromium 51 to haemoglobin. Nature 1961; 189:1019–20.10.1038/1891019a013733788Search in Google Scholar

13. McCurdy PR. ³²DFP and ⁵¹Cr for measurement of red cell life span in abnormal hernoglobin syndromes. 1969;33:214–17.Search in Google Scholar

14. Vichinsky EP, Earles A, Johnson RA, Hoag MS, Williams A, Luhin B. Alloimmunization in sickle cell anemia and transfusion of racially unmatched blood. N Engl J Med 1990;322:1617–21.10.1056/NEJM199006073222301Search in Google Scholar

15. Orlina AR, Unger PJ, Koshy M. Posttransfusion alloimmunization in patients with sickle cell disease. Am J Hematol 1978;5:101–6.10.1002/ajh.2830050204Search in Google Scholar

16. Coles SM. Klein HG. Holland PV. Alloimmunization in two multitransfused patient populations. Transfusion 1981; 21:462-610.1046/j.1537-2995.1981.21481276005.xSearch in Google Scholar

17. Rosse WF, Gallagher D, Kinney TR, et al. Transfusion and alloimmunization in sickle cell disease. Blood 1990;76;1431–7.10.1182/blood.V76.7.1431.1431Search in Google Scholar

18. Luban NLC. Variability in rates of alloimmunization in different groups of children with sickle cell disease: effect of ethnic background. Am J Pediatr Hem/Oncol 1989;11:314–19.Search in Google Scholar

19. Alarif L, Castro O, Ofosu M, Dunston G, Scott RB. HLA-B35 is associated with red cell alloimmunization in sickle cell disease. Clin lmmuno lmmunopathol 1986;38:178–83.10.1016/0090-1229(86)90136-4Search in Google Scholar

20. Michail-Merianou V, Pamphili-Panouspoulou L, Piperi-Lowes L, Pelegrinis E, Karaklis A. Moimmunization to red cell antigens in thalassemia: comparative study of usual versus better-match transfusion programmes. Vox Sang 1987;52:95–8.10.1111/j.1423-0410.1987.tb02999.x3300026Search in Google Scholar

21. Amhruso DR, Githens JH, Alcorn R, Dixon DJ, Brown LJ, Vaughn WM, Hays T. Experience with donors matched for minor blood group antigens in patients with sickle cell anemia who are receiving chronic transfusion therapy. Transfusion 1987;27:94–8.10.1046/j.1537-2995.1987.27187121485.x3810834Search in Google Scholar

22. Paten E, Patel Soto B, Gayle R. Transfusion management of patients with sickle cell disease. Ann NY Acad Sci 1989; 565:446–8.10.1111/j.1749-6632.1989.tb24220.xSearch in Google Scholar

23. Blumberg N, ROSS K, Aliva E, Peck K. Should chronic transfusion be matched for antigens other than ABO and Rho(D)? Vox Sang 1984;47:205–8.Search in Google Scholar

24. Beattie KM, Shafer AW. Broadening the base of a rare donor program by targeting minority populations. Transfusion 1986;26:401–4.10.1046/j.1537-2995.1986.26587020111.x3765029Search in Google Scholar

25. Cox JV, Steane E, Cunningham G, Frenkel EP. Risk of alloimmunization and delayed hemolytic transfusion reactions in patients with sickle cell disease. Arch Intern Med 1988;148:2485–9.10.1001/archinte.1988.00380110115024Search in Google Scholar

26. Moore SB, Taswell HF, Pinea AA, Sonnenherg CL. Delayed hemolytic transfusion reactions: evidence of the need for an improved pretransfusion compatibility test. Am J Clin Pathol 1980;74:947.10.1093/ajcp/74.1.947395821Search in Google Scholar

27. Diamond WJ, Brown FL, Bitterman P, Klein HG, Davey RJ, Winslow RM Delayed hemolytic transfusion reaction presenting a sickle-cell crisis. Ann Int Med 1980;93:231–3.10.7326/0003-4819-93-2-2317406372Search in Google Scholar

28. Solanki D, McCurdy PR. Delayed hemolytic transfusion reactions. JAMA 1978;239:729–31.10.1001/jama.1978.03280350053013Search in Google Scholar

29. Bove J. Delayed complications of transfusion. Conn Med J 1968;32:38.Search in Google Scholar

30. Rao KRP, Patel AR Delayed hemolytic transfusion reactions in sickle cell anemia. Southern Med J 1989;82:1034–6.10.1097/00007611-198908000-000252762885Search in Google Scholar